Evidence map›Paper›PMID 28123572›Full record

ArticleOncology letters2017

Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance

Jingling Tang, Hongyu Ji, Jinmei Ren, Mengting Li, Nannan Zheng, Linhua Wu

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jingling TangDepartment of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
Hongyu JiDepartment of Pharmacy, The Second Affiliated Hospital, Harbin Medical University, Key Laboratory of Medications Research, College of Heilongjiang Province, Harbin, Heilongjiang 150086, P.R. China.
Jinmei RenDepartment of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China; Department of Pharmacy, The Second Affiliated Hospital, Harbin Medical University, Key Laboratory of Medications Research, College of Heilongjiang Province, Harbin, Heilongjiang 150086, P.R. China.
Mengting LiDepartment of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China; Department of Pharmacy, The Second Affiliated Hospital, Harbin Medical University, Key Laboratory of Medications Research, College of Heilongjiang Province, Harbin, Heilongjiang 150086, P.R. China.
Nannan ZhengDepartment of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
Linhua WuDepartment of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China; Department of Pharmacy, The Second Affiliated Hospital, Harbin Medical University, Key Laboratory of Medications Research, College of Heilongjiang Province, Harbin, Heilongjiang 150086, P.R. China.
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) is a main clinical hurdle for chemotherapy of cancer, and overexpression of P-glycoprotein (P-gp) is a key factor. In the present study, a new co-delivery system for reversing MDR was designed and developed. The system was composed of curcumin (Cur) and piperine (Pip) encapsulated in solid lipid nanoparticles (SLNs) with tocopheryl polyethylene glycol succinate (TPGS) and Brij 78 [(Cur+Pip)-SLNs]. TPGS and Brij 78 could sensitize MDR tumors by inhibiting the P-gp drug efflux system. The combination of Cur and Pip, when administered in SLNs formulations, resulted in a significant enhancement in cytotoxicity and allowed efficient intracellular delivery of the drugs in drug-resistant A2780/Taxol cells. This dual inhibitory strategy may have significant potential in the clinical management of MDR in cancer.

Indexed as

curcuminmultidrug resistanceP-glycoproteinpiperinesolid lipid nanoparticles

Identifiers

PMID28123572
PMCPMC5245101
OpenAlexW2552653244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.